EVI is contributing to the global efforts to control diseases of poverty and emerging infectious diseases in three main ways:
- Creating an environment to accelerate the development and clinical assessment of vaccine candidates
- Promoting affordability and accessibility of vaccines in low income populations
- Seeking to align all major stakeholders and acting as a focal point to ensure the successful development of vaccines for low income populations.
The current EVI portfolio comprises vaccine candidates for diseases of poverty such as malaria, leishmaniasis and others. Moreover, EVI is increasingly focusing on emerging infectious diseases and is, for example, promoting the development of a vaccine against the Zika virus.
EVI continues to advance successfully the development of a variety of vaccine candidates into clinical development. To date, EVI has supported the development of more than thirty vaccine formulations, seventeen of which have progressed into early clinical development.